The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis. I’m excited to report about the combined results from two clinical trials on Risankizumab
Read Article
Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis). A report from ACR 2021 (Abstract 1713) examined the risk
Read Article
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Read Article
My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.
Read Article
Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been
Read Article
Links:
Links:
Links:
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
Links:
A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.
Read Article
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Read Article
Pedro Castillo @_Castillo_Pedro( View Tweet )
Pedro Castillo @_Castillo_Pedro( View Tweet )
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Read Article
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of
Read Article
Janet Pope @Janetbirdope( View Tweet )
Links:
Pedro Castillo @_Castillo_Pedro( View Tweet )
Links:
Discussions on drug safety can be as treacherous as quicksand for the patient and physician. What the physician knows and what the patient perceives may not be in sync.
Read Post
